Antiretroviral therapy effectively suppresses HIV replication, but latent viral reservoirs remain the principal barrier to a cure. In infants receiving early ART, suppression coincides with a critical period of immune-system development. The pediatric reservoir therefore differs biologically from reservoirs established in adults.

Reviewing the available evidence, the authors describe smaller reservoirs and reduced viral diversity after early treatment, alongside a greater proportion of less-differentiated infected cells and lower expression of exhaustion markers. These characteristics may help explain why pediatric reservoirs behave differently from adult reservoirs. A smaller founding population and lower viral diversity could limit the cellular and viral variation available for clonal expansion and immune-driven viral evolution.

Reservoir measurements also depend on the assays selected and on the cellular or tissue compartments examined. The review identifies cellular and tissue compartmentalization as important determinants of how reservoir persistence is interpreted. Different assays can produce differing estimates of reservoir size, composition and persistence, so apparently inconsistent results require careful comparison of methods.

The authors emphasize that a clearer account of reservoir establishment, maintenance and dynamics is needed before age-appropriate latency-reversing, immunotherapeutic and gene-based interventions can be designed and evaluated. The relatively small and less diverse reservoirs observed after early treatment, together with better-preserved immune function, may provide a more favorable setting in which to test cure-oriented strategies. Progress will nevertheless depend on distinguishing the comparatively well-supported reduction in initial seeding from the less definitive, longitudinal and observational evidence for continued reservoir decay under sustained suppression.

Subject of Research: Immunobiology and persistence of HIV reservoirs in children receiving early antiretroviral therapy

Article Title: Pediatric HIV reservoir in early ART: distinct immunobiology and its implications for HIV cure

Article References: Kamvuma, K., Obeagu, E. I., Phiri, S. B., Kapoma, C., Mudenda, S., Simpamba, E., Sichamba, P., Ademola, Y. U., Mulemena, J., Chanda, W., Nzobokela, J., Chiyenu, K., Mutalange, M., & Munsanka, S. (2026). Pediatric HIV reservoir in early ART: distinct immunobiology and its implications for HIV cure. Virology Journal. https://doi.org/10.1186/s12985-026-03336-6

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03336-6

Keywords: pediatric HIV, antiretroviral therapy, viral reservoir, latent HIV, CD4⁺ T cells, immune exhaustion, viral diversity, viral suppression, HIV cure research, reservoir seeding, Pediatric, reservoir

The central obstacle to curing HIV is the latent reservoir: a population of CD4-expressing cells carrying transcriptionally silent but intact proviruses. Antiretroviral therapy (ART) suppresses plasma viraemia indefinitely but does not touch these cells. Cells with actively expressed provirus can be attacked by broadly neutralizing antibodies, but latently infected cells expose no viral proteins and therefore cannot be selectively targeted without first forcing the virus out of hiding. To date, the only interventions that have convincingly eliminated the reservoir are cytotoxic conditioning regimens and allogeneic stem-cell transplantation from donors carrying the CCR5-Δ32 mutation, which renders the receptor non-functional and blocks entry of most HIV strains.

Previous early-treatment experiments in macaques have been uniformly disappointing. When ART was initiated three or seven days after SIV or SHIV infection, no animals achieved remission. In one large study using a low-dose intravenous inoculum designed to model slow human transmission, only one of thirteen animals treated six days after infection failed to rebound, and none treated at seven days did. Even allogeneic stem-cell transplantation in Mauritian cynomolgus macaques, which can produce cure, is sometimes defeated by viral spread to engrafting CCR5-positive donor cells. The new study therefore asked a different question: rather than relying on ART alone, could the cells that harbour and sustain the early reservoir be physically removed?

The experimental design was deliberately aggressive. Twenty-five newborn rhesus macaques were randomized at birth, and at roughly two to three weeks of age they received a high oral dose of SIVmac251, a highly pathogenic and genetically heterogeneous swarm virus. The animals were left untreated for seven days to allow a permanent, systemic infection to establish, then placed on a triple antiretroviral regimen of tenofovir, emtricitabine and dolutegravir. Two days after ART initiation, one group continued on ART alone, a second received a CD4-depleting antibody called CD4R1, and a third received a single intravenous dose of an anti-CCR5/CD3 bispecific antibody, a molecule engineered to bind CCR5 on target cells and CD3 on T cells, thereby recruiting T cells to destroy any cell expressing CCR5. ART was withdrawn after eighteen weeks and viral rebound was monitored.

Twenty of the twenty-five infants were successfully infected, and all infected animals showed unambiguous systemic SIV infection with repeated plasma viral-load detections and cell-associated viral RNA. Both depleting antibodies accelerated the decline in plasma viraemia compared with ART alone, with statistically significant steeper slopes of decay in both antibody groups. The team also tracked cell-associated SIV DNA before and after depletion: control animals showed an average drop of 1.7 log units, CD4R1 recipients 2.7 log units, and bispecific antibody recipients 3.4 log units, a statistically significant advantage for the CCR5-targeting strategy. Notably, about ninety-five percent of proviruses detected during this early phase were intact, meaning the measured depletion applied to the replication-competent fraction of the reservoir rather than defective debris.

The immunological consequences of the two antibodies differed in instructive ways. CD4R1 produced profound and durable depletion of CD4-positive T cells and monocytes, with deficits persisting in some animals for twelve weeks. The bispecific antibody first caused a temporary CD3-positive lymphopenia that resolved within about four weeks, followed by a remarkably specific and long-lasting loss of CCR5-expressing cells. Circulating CCR5-positive memory CD4 and CD8 T cells were essentially eliminated, with three or fewer CCR5-positive CD4 memory cells per millilitre of blood detected for at least fourteen weeks after a single administration, and relative depletion persisting in some animals for thirty-four weeks or longer. Multiplex cytokine assays showed no significant inflammatory response attributable to the treatment, and the animals tolerated the procedure well, gaining weight comparably to controls, with only mild, transient hypersensitivity-type reactions in a few individuals.

The virological outcomes after ART withdrawal were striking. Every control animal rebounded within seven days, and six of eight CD4R1-treated animals rebounded within the same window. Among the seven bispecific antibody recipients, the first two rebounds did not occur until thirteen days after treatment interruption. Four others delayed rebound to ninety-seven or one hundred seventy-three days, or never rebounded at all during follow-up, which extended to twenty-nine weeks in one case and four years in another. A Cox proportional hazards model incorporating peak viral load and treatment group showed that both lower peak viraemia and bispecific antibody treatment independently delayed rebound, with the model estimating a ninety-five percent reduction in rebound hazard attributable to the bispecific antibody. Inheritance of protective MHC alleles did not predict outcome.

To determine whether the non-rebounding animals had truly cleared the virus, the researchers subjected three animals in durable remission to a battery of the most demanding tests available. High-sensitivity quantitative PCR with a detection limit of four copies per millilitre found no residual viraemia. The animals were then depleted of CD8-positive T cells with a rhesusized anti-CD8 antibody to remove any cytotoxic T lymphocyte control that might be suppressing hidden virus; rebound still did not occur, indicating that CD8 cells were not the mechanism of remission. Two of the animals were necropsied, and bone marrow, intestine, lung, spleen and multiple lymph nodes were examined by qPCR and by RNAscope and DNAscope in situ hybridization. No viral RNA or DNA was detected in any tissue, in sharp contrast to a viraemic control animal in which all six tissues tested were positive. Viral outgrowth assays from lymph-node cells failed to recover SIV in eight of eight attempts involving tens of millions of cells.

Mathematical modelling of the rebound data provided a quantitative estimate of how much the reservoir had shrunk. Using statistical tools that integrate viral-load and outgrowth information to infer the rate at which the remaining reservoir produces actively infected cells, the model estimated that CD4R1 treatment was associated with roughly a thirteenfold to twentyfold reduction in reservoir size, while the bispecific antibody was associated with a reduction of roughly 152-fold to 219-fold, after correcting for peak viral load and protective MHC alleles. These figures fall short of the two-thousand-fold reduction that modelling suggests is needed to delay rebound by a year in most people, which points to a second mechanism beyond simple cell killing. The authors argue that removing CCR5-positive cells also strips the virus of the targets it needs: reactivated virions encounter few infectable cells, nascent infectious foci cannot spread, and the residual reservoir decays through viral cytopathicity and cellular attrition. The case of the so-called Chicago patient, who achieved prolonged remission after a CCR5-Δ32 transplant despite a persistent reservoir, supports the idea that ART can be curative when infectable targets are scarce.

Several caveats temper the excitement. The intervention was delivered within days of infection, when the reservoir is small and still dominated by CCR5-positive cells; in chronic infection, the reservoir shifts toward memory and stem-cell-like CD4 subsets whose relationship to CCR5 is weaker, so the strategy may not translate directly to adults with long-standing HIV. The bispecific antibody also depletes CCR5-positive CD8 T cells and other uninfectable cells, raising questions about susceptibility to opportunistic infections, although lifelong CCR5 deficiency in Δ32 homozygotes is generally well tolerated apart from increased risk of symptomatic West Nile virus disease. It is also possible that part of the benefit comes from CCR5 blockade acting as an entry inhibitor rather than from depletion alone. Even so, the study demonstrates for the first time that a pharmacological intervention, a single shot, can achieve meaningful depletion of the replication-competent lentiviral reservoir and produce durable, apparently complete clearance in an animal model. For infants treated very soon after infection, and potentially as a component of combination immunotherapy for older patients, the result reopens a route to HIV cure that many in the field had considered closed.

Subject of Research: Depletion of the SIV reservoir in neonatal macaques using a CCR5/CD3 bispecific antibody

Article Title: SIV reservoir depletion and clearance from neonatal macaques following transient CCR5 depletion

Article References: Deere, J. D., Merriam, D., Machmach, K., Chang, W. L. W., Nekorchuk, M., Méndez-Lagares, G., Kieu, H., Dutra, J., Fontaine, J., Andal, D. R., Sipe, K., Heninger, E., Martin, M., Lu, W., Chin, N., Chen, C., Tran, B. C.-T., Salinas, J., Miller, C. N., … Hartigan-O’Connor, D. J. (2026). SIV reservoir depletion and clearance from neonatal macaques following transient CCR5 depletion. Nature Microbiology. https://doi.org/10.1038/s41564-026-02511-3

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02511-3

Keywords: HIV, SIV, viral reservoir, CCR5, bispecific antibody, macaques, antiretroviral therapy, latent infection, viral rebound, HIV cure, immunotherapy, neonatal infection

The study, known as DUALITY, examined first-line therapy with dolutegravir and lamivudine, a two-drug combination that has become a recommended starting regimen for people living with HIV-1. Traditional antiretroviral therapy typically relies on three drugs from at least two classes, but dolutegravir, a potent integrase strand transfer inhibitor, has such a high genetic barrier to resistance that researchers have increasingly tested whether pairing it with the nucleoside reverse transcriptase inhibitor lamivudine could maintain full viral suppression while halving drug exposure. The approach has already proven effective at suppressing virus in the blood, but a critical question lingered: would two drugs maintain adequate concentrations in lymphoid tissue, where HIV establishes its most stubborn reservoirs?

Lymph nodes are not merely passive filters; they are the architectural hubs of the immune system, densely packed with CD4-positive T cells, the preferred targets of HIV. During untreated infection, these tissues become sites of explosive viral replication and profound structural damage. Even after years of suppressive therapy, when blood tests show no detectable virus, lymphoid tissues can harbor infected cells carrying transcriptionally silent proviral DNA. These reservoirs are the principal obstacle to any cure, and they have long raised concerns that reduced-drug regimens might leave pockets of residual replication unaddressed in tissue compartments where drug penetration could be weaker than in blood.

To address that concern, the DUALITY investigators randomized participants to initiate either the two-drug dolutegravir-lamivudine regimen or a standard dolutegravir-based triple therapy. The trial’s prespecified primary endpoint, the change in proviral HIV-1 DNA in peripheral blood CD4-positive T cells from baseline to week 48, was similar between the two groups, reinforcing earlier evidence that the simplified regimen performs comparably to conventional triple therapy in suppressing the measurable blood reservoir. But the blood is only part of the story, and the team designed a series of secondary analyses to look inside the tissues themselves.

Thirty-nine participants underwent surgical excision of an inguinal lymph node, either at the start of treatment or during the first year of therapy. These tissue samples became the foundation for a remarkably detailed multimodal imaging campaign. Using DNAscope and RNAscope, in situ hybridization techniques that can detect individual HIV-1 DNA and RNA molecules within intact tissue sections, the researchers visualized infected cells directly in their anatomical context. In parallel, they applied mass spectrometry imaging, a technology that maps the spatial distribution of small molecules across a tissue section pixel by pixel, to chart exactly where dolutegravir and lamivudine, along with other antiretrovirals, accumulated within the same lymph node specimens.

The results were striking on both fronts. First, HIV-1-infected cells declined rapidly after treatment initiation across both treatment groups, indicating that the two-drug regimen suppressed viral replication in lymphoid tissue just as effectively as triple therapy. Second, and perhaps more importantly for the field, the mass spectrometry imaging showed that antiretrovirals were widely detected within lymph node tissue regions containing HIV-positive cells or directly adjacent to them. In other words, the drugs were not merely present in the tissue in bulk; they were reaching the very neighborhoods where the virus persists, extending the picture of pharmacological coverage from the bloodstream into a key anatomical reservoir.

This spatial evidence matters because pharmacological sanctuary sites have been a persistent worry in HIV therapy design. Tissue penetration varies substantially among antiretroviral drugs, influenced by factors such as protein binding, molecular size, and active transport mechanisms at tissue barriers. If a two-drug regimen failed to achieve effective concentrations in lymphoid tissue, low-level residual replication could theoretically continue unnoticed, gradually replenishing the reservoir and eroding the durability of suppression. The DUALITY imaging data argue against that scenario for dolutegravir and lamivudine, showing co-localization of drug signal and viral signal within the same tissue microenvironments.

The technical achievement underlying these conclusions should not be understated. Detecting HIV-1 DNA and RNA by in situ hybridization in suppressed patients is analytically demanding, because infected cells are rare and the viral signal is faint. Mass spectrometry imaging of antiretrovirals in human tissue is similarly specialized, requiring careful method validation to distinguish true drug signal from background. By combining these modalities on the same lymph node sections, the research team, which spanned institutions including the University of North Carolina at Chapel Hill, Oregon Health and Science University, and the Germans Trias i Pujol research community in Badalona, Spain, could align viral geography with drug geography at a resolution that bulk tissue homogenization could never provide.

The trial was sponsored by Fundació Lluita contra les Infeccions and funded by ViiV Healthcare and the National Institutes of Health, with the academic investigator team retaining responsibility for study design, data analysis, and interpretation. As an open-label randomized study, it carries the usual caveats of unblinded design, and the number of lymph node excisions, while substantial for this kind of invasive tissue sampling, remains modest. The authors also note that the published version was shared early to accelerate access to the peer-reviewed findings. Nonetheless, the convergence of the primary blood-based endpoint and the tissue-level imaging results presents a coherent picture of two-drug therapy performing robustly across compartments.

For clinicians and patients, the findings add mechanistic reassurance to a regimen already validated by large outcome trials: dolutegravir plus lamivudine does not appear to leave the lymph nodes under-protected. For cure researchers, the study demonstrates a template for evaluating future interventions, whether simplified regimens, long-acting formulations, or reservoir-purging strategies, by directly measuring whether drugs and viral targets overlap in tissue. As the search for strategies that might eventually shrink or eliminate the HIV reservoir continues, knowing that first-line two-drug therapy reaches the cells it needs to reach is a meaningful step forward in ensuring that simplification does not come at the cost of silent viral persistence.

Subject of Research: Lymph node penetration of two-drug dolutegravir/lamivudine HIV-1 therapy and its effect on the viral reservoir

Article Title: First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial

Article References: Rosen, E. P., Bondoc, S., Bailón, L., Blay, L., Caballero, A., García-Guerrero, M. C., Puertas, M. C., Moraes-Cardoso, I., Vazquez-Escobales, A., Blanco, J., Mothe, B., Kashuba, A. D., Estes, J. D., Martinez-Picado, J., Molto, J., On behalf of the DUALITY study group, Rosen, E. P., Bondoc, S., Bailón, L., … White, N. (2026). First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial. Nature Communications. https://doi.org/10.1038/s41467-026-78190-9

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78190-9

Keywords: HIV-1, dolutegravir, lamivudine, lymph nodes, viral reservoir, antiretroviral therapy, clinical trial, mass spectrometry imaging, DNAscope, RNAscope, proviral DNA, two-drug regimen

Antiretroviral therapy transformed HIV from a nearly uniform death sentence into a manageable chronic condition by blocking new rounds of infection. Yet the therapy does nothing to the proviral DNA already stitched into the genomes of long-lived host cells. As soon as treatment lapses, the reservoir seeds rapid viral rebound. Understanding why particular infected clones persist for years, while others decay, has therefore become one of the most consequential questions in HIV research, and the new findings suggest the answer lies partly in the immune environment the reservoir cells inhabit rather than in the virus alone.

Natural killer cells are innate lymphocytes that patrol the body and kill stressed or infected cells without requiring the antigen-specific recognition that defines T and B lymphocytes. Their activity is governed by a delicate balance of activating and inhibitory receptors. KIR2DL1 is an inhibitory killer-cell immunoglobulin-like receptor that recognizes specific HLA class I molecules, the same surface proteins that HIV-exposed cells display. The education model of NK cell biology holds that a developing NK cell calibrates its functional competence through interactions between its inhibitory receptors and self-HLA; a KIR2DL1-positive NK cell in an individual carrying the corresponding HLA ligand becomes ‘educated,’ or licensed, to respond vigorously when that ligand is lost or altered, as frequently happens during viral infection.

The study demonstrates that these education states are not a fleeting influence but leave durable imprints on the reservoir. By examining cells from people who had spent years, in some cases many years, on suppressive antiretroviral regimens, the researchers found that proviruses surviving over the long term were not distributed randomly across the infected cell population. Instead, their persistence correlated with features of the innate immune landscape, indicating that some infected cells had been preferentially spared or eliminated depending on how the NK cell compartment of that individual had been trained.

This reframes the reservoir as an active participant in a prolonged evolutionary standoff with the immune system. Cells harboring intact, replication-competent proviruses that somehow avoid NK-mediated killing gain a survival advantage and expand, sometimes through clonal proliferation, over years of therapy. Cells that present vulnerabilities to educated NK cells are progressively culled. The result is a reservoir sculpted by immune pressure, analogous in some respects to how antigen escape shapes the evolution of the virus in untreated infection, but operating here through germline-encoded innate receptors rather than clonal adaptive recognition.

The technical achievement underlying these conclusions is considerable. Single-cell approaches now allow researchers to connect proviral sequence, integration site, transcriptional state, and surface phenotype in the same individual cell, converting what was once a population-level average into a high-resolution map of reservoir heterogeneity. Combined with deep characterization of NK cell receptor repertoires and their HLA ligands in each study participant, such methods make it possible to ask which immune configurations leave measurable signatures on which reservoir lineages, and the study deployed precisely this integrative strategy across cohorts on long-term therapy.

The clinical implications are potentially far-reaching. Current cure strategies aim to ‘shock and kill’ the reservoir, using latency-reversing agents to force latent proviruses into expression so that immune or pharmacological effectors can destroy the exposed cells. If KIR2DL1-educated NK cells already exert selection pressure on the reservoir, then the efficiency of such interventions may depend heavily on whether the killing arm of the strategy is matched to the individual’s NK cell education status and HLA type. A shock-and-kill regimen delivered to a person whose NK cells are poorly licensed against their own reservoir cells might flush virus into the open without achieving meaningful depletion.

This line of thinking points toward precision immunotherapies for HIV. Just as cancer immunotherapy increasingly considers the tumor microenvironment and the patient’s innate immune competence, curative interventions for HIV may need to account for innate immune imprints. Engaging NK cells deliberately, through bispecific killer-cell engagers, cytokine modulation, or engineered NK products, could in principle tip the standoff in favor of the host. Conversely, therapies that inadvertently impair NK education or function might relax selection pressure and allow reservoir clones to expand unchecked during what was assumed to be stable suppression.

The findings also resonate with a broader shift in virology: the recognition that innate immunity is not merely a rapid first response but a long-lived determinant of infection outcomes. Trained immunity, NK cell memory-like behavior, and receptor education all illustrate that innate cells carry histories. In chronic infections treated for years with suppressive drugs, those histories accumulate and leave fingerprints on the surviving pathogen population. HIV, the most intensively studied persistent human virus, now appears to bear such fingerprints in its reservoir.

Substantial questions remain. The relationship between KIR2DL1 education and reservoir persistence will need to be validated across larger and more diverse cohorts, since KIR and HLA genotype distributions vary substantially across populations, and HIV epidemiology is concentrated in regions where such genetic diversity is greatest. Whether innate selection can be therapeutically harnessed to shrink the reservoir, or only to shape it, is unresolved. But the conceptual contribution is clear: the latent HIV reservoir is not hidden from the immune system in any absolute sense. It has been living under innate immune surveillance all along, and the cells that persist during long-term antiretroviral therapy are, in part, the survivors of that surveillance. Any credible path to a cure will have to reckon with the imprints that this ancient arm of immunity has already left on the virus’s last refuge.

Subject of Research: The influence of KIR2DL1-educated natural killer cells on the persistence of latent HIV-1 reservoir cells during long-term antiretroviral therapy.

Article Title: Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy

Article References: Tan, T. S., Sun, W., Gao, C., Viard, M., Walters, L. C., Lancien, M., Yuki, Y., Van, T. N., Casquero, C., Guo, X., Hoh, R., Haas, D. W., Michael, N., Kirk, G. D., Yendewa, G., Gandhi, R. T., Kassaye, S. G., Tien, P. C., Walker, B. D., … Lichterfeld, M. (2026). Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy. Nature Immunology. https://doi.org/10.1038/s41590-026-02637-w

Image Credits: AI Generated

DOI: 10.1038/s41590-026-02637-w

Keywords: HIV-1, viral reservoir, natural killer cells, KIR2DL1, NK cell education, antiretroviral therapy, viral latency, innate immunity, HIV cure research, Nature Immunology, immunotherapy, proviral persistence

The research, conducted in rhesus macaques infected with simian immunodeficiency virus, examined the consequence of administering an inhibitor of BCL-2 at the same time antiretroviral therapy was begun. BCL-2 is the founding member of a family of proteins that govern the intrinsic pathway of apoptosis, the programmed death machinery residing in the mitochondria of every nucleated cell. These proteins operate through a delicate balance: pro-survival members such as BCL-2, BCL-XL and MCL-1 sequester pro-apoptotic effectors like BAX and BAK, keeping the mitochondrial outer membrane intact. When the balance tips — through cellular stress, growth-factor withdrawal, or pharmacological inhibition — the effectors oligomerize, the membrane permeabilizes, and cytochrome c is released, committing the cell irreversibly to death. Lymphoid cells, and in particular long-lived memory T cells, depend heavily on BCL-2 for their extended lifespan, which is precisely why the latent reservoir exploits this pathway to survive the years of treatment that follow infection.

The rationale for the intervention rests on a conceptual reframing of the reservoir problem. Latency-reversing approaches attempt to shock the virus out of hiding and rely on the immune system or viral cytopathic effects to destroy the cells that harbor it. The BCL-2 strategy instead attacks the survival advantage of the infected cells themselves, arguing that if a latently infected cell can be nudged across the apoptotic threshold while the patient’s cells are protected from ongoing infection by ART, the intact reservoir should contract without the need for viral reactivation. This idea draws on clinical experience from oncology, where selective BCL-2 inhibitors such as venetoclax have transformed the treatment of chronic lymphocytic leukemia by triggering apoptosis in malignant lymphocytes that overexpress the protein. Repurposing that pharmacology for HIV cure research has long been proposed in model systems, but rigorous in vivo evidence that the approach works against the intact reservoir, in a setting that faithfully recapitulates human infection, had been lacking.

In the macaque study, animals infected with SIV received antiretroviral therapy accompanied by BCL-2 inhibition beginning at the time of treatment initiation, while control animals received ART alone. The investigators then tracked the composition of the reservoir over the course of suppression using quantitative methods capable of distinguishing intact proviruses from defective ones — an essential technical distinction, since measures that count all proviral DNA or rely solely on replication-competence assays can be dominated by defective genomes that pose no clinical threat. Single-genome sequencing approaches, in which viral genomes are amplified and analyzed individually, allow researchers to categorize each provirus as genetically intact or defective and to estimate the true size of the replication-competent reservoir. It is this intact-reservoir metric that predicts how long rebound would take after treatment interruption and that any realistic cure strategy must reduce.

The results demonstrated that the combined regimen reduced the frequency of intact SIV proviruses to a greater degree than ART alone. This finding carries significance well beyond the raw numbers. In the standard macaque model of ART suppression, the intact reservoir decays slowly and incompletely, mirroring the stubborn persistence observed in treated people living with HIV. An intervention applied at the start of therapy that accelerates this decay suggests that early intervention — the period in which the reservoir is being seeded and consolidated — represents a window of vulnerability that has been underexploited. Cells harboring latent virus during this period may be especially dependent on BCL-2-mediated survival, perhaps because they belong to recently activated, cytokine-dependent lineages that have not yet achieved the deep quiescence of long-term memory cells, or because the perturbation of the cellular environment by treatment initiation renders them more sensitive to apoptotic priming.

Timing is a theme that recurs throughout the reservoir literature, and the placement of BCL-2 inhibition at therapy initiation rather than during established suppression is one of the study’s most consequential design choices. A large body of observational work in humans has shown that the size of the reservoir is strongly determined by how quickly ART is started after infection; treatment during acute infection produces a smaller reservoir that, in rare cases, permits sustained remission after analytic treatment interruption, as famously demonstrated in the Mississippi child and a cohort of post-treatment controllers. The macaque data now suggest that pharmacological manipulation of cell-survival pathways can augment that early-treatment advantage. By pairing BCL-2 inhibition with the first days of ART, the intervention may eliminate infected cells at a stage when the reservoir is most dynamic and most chemically vulnerable, before proviruses disperse into the heterogeneous, long-lived populations that make later cure attempts so difficult.

The mechanistic logic of the approach also deserves attention. Unlike broadly neutralizing antibodies or therapeutic vaccines, which act on the viral side of the host-pathogen interface, BCL-2 inhibitors modulate host biology, raising the specter of on-target toxicity: excessive apoptosis of bystander lymphocytes, immunosuppression, or hematologic complications. The anti-apoptotic family is redundant, with different members protecting different cell lineages, and selective inhibition of BCL-2 alone is generally tolerated in leukemia patients, where the drug’s therapeutic window has been mapped in detail. Nevertheless, translating a cancer dosing schedule to an infectious-disease indication in otherwise healthy carriers requires careful attention to CD4+ and CD8+ T cell counts, neutrophil dynamics, and the possibility of transient cytokine release from dying cells. The macaque model, with its close immunological correspondence to humans and its validated SIV challenge system, provides the appropriate preclinical platform for establishing that window, and the observed reduction of the intact reservoir without catastrophic loss of immune competence represents an encouraging early signal.

Broader implications extend to the architecture of cure strategies as a whole. The field has converged on the view that no single intervention will eradicate the reservoir; combination regimens — pairing a reservoir-reduction modality with an immune effector such as broadly neutralizing antibodies, and a means of protecting uninfected cells such as long-acting antiretrovirals — are widely considered necessary. A BCL-2-directed agent could plausibly occupy the reduction slot in such combinations, working synergistically with latency-reversal approaches by first shrinking the intact pool and then rendering residual infected cells more susceptible to immune clearance. The study also reinforces a growing appreciation that the intracellular death machinery is a legitimate pharmacological target in virology, opening a search for other host-survival dependencies — metabolic, epigenetic, or signaling-based — that latently infected cells might share and that could be exploited with existing drugs.

Substantial questions remain before any human application. The durability of the reduction, its reproducibility across animals with different reservoir sizes and infection timelines, the effect of delaying inhibition until after prolonged suppression, and the interaction with viral rebound dynamics all require further investigation. Human reservoir biology differs from the macaque model in heterogeneity and scale, and the intact reservoir in chronically infected adults is orders of magnitude larger than in early-treated cases, which may limit what a survival-pathway intervention can achieve late in disease. Yet the study’s core contribution is conceptual as much as empirical: it shows in a rigorous animal model that the intact reservoir — not merely the total proviral burden — can be attacked by targeting the host determinants of cellular longevity, and that treatment initiation offers a pharmacologically exploitable moment to do so. As cure research matures beyond proof-of-concept latency reversal, strategies of this kind may help define a realistic path toward functional remission, in which residual virus is so scarce and so fragile that antiretroviral therapy can be safely suspended for extended periods.

Subject of Research: BCL-2 inhibition combined with antiretroviral therapy to reduce the intact simian immunodeficiency virus reservoir in macaques

Article Title: BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques

Article References: Wiche Salinas, T. R., Harper, J., Deleage, C., Nguyen, K., Auger, J., Flores, H. R., Kaushik, S. R., Wilkes, A. C., Stammen, R. L., Wood, J. S., Easley, K. A., Nelson, S., Tharp, G. K., Bosinger, S. E., Cottrell, M. L., Kose, E., Immonen, T. T., Lifson, J. D., Laird, G. M., … Paiardini, M. (2026). BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques. Nature Microbiology. https://doi.org/10.1038/s41564-026-02464-7

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02464-7

Keywords: HIV cure, SIV, viral reservoir, BCL-2, apoptosis, antiretroviral therapy, latency, CD4+ T cells, macaques, provirus, treatment interruption, Nature Microbiology